Core Insights - Eupraxia Pharmaceuticals announced positive clinical data from its ongoing RESOLVE Phase 1b/2a trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE) [1][3] - The trial has shown improvements in both tissue health and symptom relief, with no serious adverse events reported [3][5] Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on precision local drug delivery, particularly for conditions with high unmet medical needs [14][15] - The company utilizes its proprietary DiffuSphere™ technology to facilitate targeted drug delivery, aiming to improve safety and efficacy compared to traditional methods [14] Clinical Trial Details - The RESOLVE trial is a multi-center, open-label, dose-escalation study evaluating the safety and efficacy of EP-104GI in adults with active EoE [9] - Cohort 6 of the trial received 16 injections of 4 mg EP-104GI, targeting the lower three-quarters of the esophagus, resulting in significant improvements in symptom relief and tissue health [4][5] Key Findings from the RESOLVE Trial - Cohort 6 demonstrated the highest symptom relief scores (SDI) and the greatest improvement in tissue health scores (EoEHSS) to date [5][6] - A mean reduction of 94% in peak eosinophil counts (PEC) was observed, with a 62% remission rate across biopsy sites [6][8] - No serious adverse events or cases of oral or gastrointestinal candidiasis were reported in any of the cohorts [5][6] Future Expectations - Cohort 7 is fully enrolled, with 12-week data expected in late Q2 2025 [10] - The company plans to explore higher dosing levels and expanded esophageal coverage in future cohorts based on the positive outcomes observed [3][5]
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis